The Selective Capex Comeback: Medtech Capital Sales in 2026

After several years of pandemic disruption, staffing shortages, inflation, and financial strain, U.S. hospital capital spending has entered a new phase. The freeze of 2020-2022 is over. Procedure volumes are recovering. Capital budgets are growing again. Yet the rebound is not a straightforward return to pre-COVID purchasing patterns.

Instead, 2026 finds medtech capital equipment sales in a disciplined, selective capex upcycle, defined by cautious optimism, intense scrutiny, longer sales cycles, and a decisive shift toward technologies that demonstrably drive revenue, efficiency, and clinical productivity.

For device makers selling capital equipment, understanding this new environment is critical.

Why This Is Important

Hospital capital equipment spending fell sharply during the pandemic, as health systems prioritized liquidity and staffing. That environment has been changing.

Hospital CFO surveys indicate U.S. hospitals expect capital spending to grow again, following a strong rebound year. A 2023 Baird survey found hospital leaders forecasted approximately 9% capital spending growth for 2024, above pre-pandemic low single-digit trends.¹ 

The recovery has continued. A 2025 survey of hospital executives² found hospital capex grew 5.8% in 2025, is expected to rise 4.7% in 2026, and nearly 60% of executives expect higher capital budgets. This reflects a healthcare sector gradually stabilizing after years of volatility. For manufacturers, this marks a significant inflection point: The market is no longer contracting—but it is far from unconstrained.

The Capital Recovery Engine

Capital spending in hospitals follows a conventional driver—procedure volumes. When utilization falls, capital spending stalls. When procedure rates return, capital budgets follow.

Surveys show clear improvement. In 2024, hospital administrators reported procedure volumes rising 2%-3% sequentially, with cardiology leading the growth.³

Another survey found almost half of hospital executives expected procedure volumes to rise 5%-6% in 2024, supported by easing staffing shortages.⁴

This recovery matters because capital purchasing typically lags utilization by 12-24 months. As COVID-related procedure backlogs continue to clear, hospitals must invest in equipment to expand capacity and support growing patient demand. The result is a structural tailwind for capital equipment sales.

A Recovery with Constraints

Despite improving demand, hospitals remain financially cautious. The capital recovery is occurring amid persistent macroeconomic and policy pressures. A TD Cowen survey² found:

• 75% of hospital executives say macro factors affect capital purchases
• 40% plan to cut or defer equipment spending
• Tariffs, interest rates, and Medicaid uncertainty remain key risks 

At the same time, the financial health of U.S. healthcare systems is divided. Approximately half report constrained finances, while the other half report stable or strong positions. This bifurcation is shaping the market. Well-capitalized health systems continue to invest aggressively. Others remain selective and cautious.⁵ The implication for medtech companies: The capital sales environment is improving, but is still highly scrutinized.

Selective Capital Allocation

If there is one defining theme of hospital capital purchasing in 2026, it is selectivity. Hospitals are not simply spending more; they are spending more strategically.

The Baird survey found hospitals prioritizing OR equipment, endoscopic cameras, and procedural tools that support elective care.¹ The reason is clear. Hospitals are preserving highly valued capital dollars for procedural tools that can better drive real-time revenues. This shift signals a major evolution in purchasing behavior. Capital equipment must now demonstrate clear and rapid economic value.

In practice, this means the strongest demand is for technologies that expand procedural capacity, increase throughput, improve labor productivity, and enable new billable services. Capital purchases without a clear ROI are increasingly under scrutiny.

Winners in the 2026 Capex Mix

Several equipment categories are benefiting directly from the recovery.

Procedural and OR Technologies—Hospitals are prioritizing tools that help address the backlog of elective procedures and increase surgical throughput. AI-powered scheduling and capacity management solutions are tools that help healthcare systems face chronic inefficiencies, delays, misrouting, and staff burnout. These systems address challenges by enhancing triage accuracy, streamlining scheduling, and automating administrative tasks.⁶ 

Systems that collect surgical data analytics to enhance efficiency, such as the OR Black Box, are another. The OR Black Box is a virtual reality system designed to make healthcare safer and more cost-effective.⁷ In a study of 132 consecutive patients, a surprising median of 20 errors per case—or 3,435 errors—was detected.⁸

Cardiology and Minimally Invasive Care—Rising cardiology volumes are expected to benefit companies such as Boston Scientific, Edwards, and Medtronic. 

Endoscopy and Imaging Upgrades—Endoscopic and OR equipment are among the top spending priorities for hospital administrators. The rule of thumb used in GI and medtech: About 15 million colonoscopies annually in the U.S. remains the industry baseline.⁹

Productivity-Enhancing Technologies—Hospitals are prioritizing investments that reduce staffing burden and improve efficiency. These categories share a common theme: They directly support revenue generation and operational efficiency.

Losers in the 2026 Capex Mix

Not all capital categories are benefiting equally. Spending on certain surgical robots and other high-ticket platforms remains under pressure. The Baird survey found no expected increase in spending on soft-tissue robotic systems, and may decline on orthopedic robotic systems.¹

This does not signal a lack of long-term interest in robotics. Instead, it reflects tighter capital discipline and longer replacement cycles. Large platform purchases increasingly require strong justification.

The New Hospital Buying Model

Beyond spending levels, hospital purchasing behavior itself is evolving with centralized decision-making, consolidating purchasing decisions across networks. This leads to fewer vendors, larger contracts, and longer sales cycles.

Medtech companies must now sell not only to clinicians but to CFOs, value analysis committees, and system-level procurement teams. Clinical value alone is no longer sufficient. Hospitals expect demand for economic evidence, clear ROI models, throughput and productivity data, and evidence of workforce impact.

An L.E.K. survey notes operational and cost efficiency now lead health system priorities.⁵ This shift is transforming capital sales into a mix of clinical, operational, and financial selling.

The Big Picture of Medtech Growth 

Despite near-term challenges, the broader medtech industry remains strong. Based on the EY Pulse of Medtech Industry Report, the global medtech market reached $584 billion in 2025, marking the seventh consecutive year of growth. Industry leaders expect 6%-7% annual revenue growth to continue.¹⁰

Investor confidence remains high. Medtech deal value reached $97.6 billion in 2025, with M&A expected to accelerate.¹¹ These trends reinforce a key point: The capital equipment slowdown was cyclical, not structural. Long-term drivers, including aging populations, chronic disease, and minimally invasive care, remain intact.

The Shift Toward Value-Based Capital Sales

The most important transformation in the capital sales environment is the rise of value-based purchasing. Hospitals are no longer asking simply, “Is this technology innovative?” They are asking, “Will this technology pay for itself—and how quickly?”

Successful capital sales now hinge on demonstrating revenue impact per case, reduction in labor costs, workflow optimization, and capacity expansion. 

This trend supports the broader shift toward value-based healthcare, where outcomes and efficiency increasingly determine reimbursement and purchasing decisions.

Implications for Medtech Commercial Strategy

For medtech companies, the evolving capital environment requires new commercial capabilities. Key success factors include:

1. Economic Storytelling—Companies must translate clinical benefits into financial outcomes.

2. Flexible Financing Models—Leasing, pay-per-use, and managed services are becoming more common as hospitals seek to preserve cash.

3. Strong Health System Partnerships—Hospitals are prioritizing vendors that can support efficiency, integration, and long-term collaboration.

4. Focus on Productivity and Workforce Impact—Technologies that help address staffing shortages have a competitive advantage.

The L.E.K. survey highlights the importance of expanding value-added services and strengthening supply-chain partnerships.⁵

Looking Ahead

So how are medtech capital equipment sales doing in 2026? The answer is nuanced. Capital budgets are growing again, procedure volumes are rising, hospitals are investing—but cautiously, and purchasing decisions are more strategic and economically driven.

The Medi-Vantage Perspective

The medtech capital equipment market has matured. The era of broad, clinically driven capital spending has been replaced by a more disciplined and value-focused environment.

For medtech companies, this is both a challenge and an opportunity. The companies that thrive will be those that can clearly demonstrate how their technologies help hospitals grow revenue, improve efficiency, and deliver better care in a financially constrained environment. The answers that turned these challenges into opportunities are available to every medtech company. The capital recovery is real, but it is selective.

References

¹ tinyurl.com/mpo260401
² tinyurl.com/mpo260402
³ tinyurl.com/mpo260403
⁴ tinyurl.com/mpo260404
⁵ tinyurl.com/mpo260405
⁶ tinyurl.com/mpo260406
⁷ tinyurl.com/mpo260407
⁸ tinyurl.com/mpo260408
⁹ tinyurl.com/mpo260409
¹⁰ tinyurl.com/mpo260410
¹¹ tinyurl.com/mpo260411

MORE FROM THIS AUTHOR: Electrophysiologists’ Priorities for Medtech in 2026

Maria Shepherd has more than 20 years of experience in marketing in small startups and top-tier companies. She founded Medi-Vantage, which provides marketing and business strategy for the medtech industry. She can be reached at [email protected].